EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression
verfasst von:
C. Antin, A. Tauziède-Espariat, M.-A. Debily, D. Castel, J. Grill, M. Pagès, O. Ayrault, F. Chrétien, A. Gareton, F. Andreiuolo, E. Lechapt, P. Varlet
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
In the central nervous system (CNS), the loss of H3K27me3 expression constitutes the hallmark of two different tumor types: diffuse midline glioma (DMG), H3K27-mutant and posterior fossa ependymoma, group PFA (PFA-EPN). In the former, mutations in histone genes (mostly H3F3A K27M and HIST1H3B K27M), present in about 97% of DMG, inhibit the activity of the Polycomb Repressive Complex 2 (PRC2) methyltransferase [1]. However, these mutations are rare in PFA-EPN (accounting for ≈ 4% of cases) [2]. Recent molecular advances have shown that the Enhancer of Zest Homologs Inhibitory Protein (EZHIP) is overexpressed (due to gene overexpression rather than mutations of the CXorf67 gene) in the large majority of PFA-EPN, and in the remaining cases of DMG showing H3K27me3 loss but lacking histone gene (H3) mutations [1‐3]. Indeed, this overexpression mimics the mechanism of histone gene mutations on PRC2 [4]. Usually, the current routine immunohistochemical (IHC) panel in pediatric neuropathology includes H3K27me3 and H3K27M antibodies but not EZHIP. The aim of our study was to evaluate the sensitivity and specificity of the EZHIP biomarker in a large cohort of pediatric tumors, including the most common tumor types, which arise in the brainstem and the posterior fossa.
We performed IHC for EZHIP using the CXorf67 antibody (Polyclonal; 1:75 dilution; Sigma-Aldrich; Bromma, Sweden) on 3 µm-thick sections of formalin-fixed, paraffin-embedded tissue samples of these tumors, performed on an Omnis automate. Our study included a total of 311 cases: 298 pediatric tumors of different subtypes (gliomas, embryonal, and ependymal tumors with a morphomolecular diagnosis including DNA-methylation profiling), and 13 posterior fossa ependymomas, Group PFB (for details see Table 1). This series includes some of the tumors previously reported [1]. The IHC were performed on whole sections in 266 cases and on a TMA (tissue microarray) of 45 ependymomas as a validation cohort which included PFA (n = 37), H3K27-mutant (n = 2) and PFB (n = 6). The IHC stainings were scored by three neuropathologists (ATE, PV and EL) independently.
Table 1
Immunohistochemical results of EZHIP in our series
Tumor types
EZHIP [n (%)]
Diffuse astrocytic and oligodendroglial tumors
Astrocytoma, IDH-mutant, grade 2
0/2 (0)
Oligodendroglioma, IDH-mutant and 1p19q codeleted, grade 2
0/3 (0)
Epithelioid glioblastoma
0/1 (0)
Astrocytoma, IDH-mutant, grade 4
0/3 (0)
DMG, H3K27-mutant
0/24 (0)
DMG, H3K27-WT with EZHIP overexpression
13/13 (100)
HGG with MSI
CMMRD
0/6 (0)
Lynch syndrome
0/4 (0)
Diffuse glioma, H3.3 G34-mutant
0/10 (0)
HGG, MYCN-amplified
0/9 (0)
Glioblastoma, IDH-WT
0/10 (0)
Other astrocytic tumors
Pilocytic astrocytoma
0/10 (0)
High-grade astrocytoma with piloid features
0/1 (0)
Pleomorphic xanthoastrocytoma with anaplastic features
0/9 (0)
Ependymal tumors
Myxopapillary ependymoma
0/6 (0)
Posterior fossa ependymoma
Group PFA
47/47 (100)
Group PFA, H3K27-mutant
0/2 (0)
Group PFB
0/19 (0)
Supratentorial EPN
YAP1-fusion-positive
0/5 (0)
C11orf95 fusion-positive
0/17 (0)
Subependymoma
0/2 (0)
Neuronal and mixed neuronal-glial tumors
Diffuse leptomeningeal glioneuronal tumor
0/1 (0)
Tumors of the pineal region
Pineoblastoma
0/10 (0)
Embryonal tumors
Medulloblastoma, group 3
0/5 (0)
Medulloblastoma, group 4
0/5 (0)
Medulloblastoma, SHH-activated
0/10 (0)
Medulloblastoma, WNT-activated
1/10 (10)a
Embryonal tumors with multilayered rosettes, C19MC-amplified
0/10 (0)
AT/RT
AT/RT MYC
1/3 (33)a
AT/RT SHH
0/4 (0)
AT/RT TYR
0/3 (0)
CNS tumor with BCOR internal tandem duplication
0/8 (0)
CNS high-grade neuroepithelial tumor with MN1 alteration
a1 case presents a focal expression of EZHIP (< 1% of tumor cells)
Anzeige
The IHC results (including the validation cohort) are detailed in Table 1. A strong and diffuse EZHIP nuclear staining (> 90% of immunopositive tumor cells) was observed in all DMG, H3-wildtype with EZHIP overexpression (n = 13) (Fig. 1A–C) and all PFA-EPN (n = 47) (Fig. 2A–C and Additional file 1: Figure S1), except the two EPN, H3K27-mutants (Fig. 2G–I). The majority of germinomas exhibited a strong nuclear immunostaining (94%, 29/31 cases) associated with a loss of H3K27me3 trimethylation (Fig. 1G–I and Additional file 2: Figure S2). In all other diagnoses, tumor cells were immunonegative except for two cases: one atypical teratoid/rhabdoid tumor (AT/RT) belonging to the MYC methylation class and one medulloblastoma, WNT-activated. These two cases exhibited only focal expression (< 1% of immunopositive tumor cells) (data not shown). This low protein expression of EZHIP was correlated with a normal level of CXorf67 gene expression at the mRNA level. Thus, the specificity and the sensitivity of the IHC were evaluated as 99% and 98% respectively.
×
×
This work constitutes the first study of the sensitivity/specificity of EZHIP immunoexpression in a large cohort of CNS tumors. Our results highlighted that nuclear EZHIP expression must be diffuse and strong to be interpreted as overexpressed. Thus, EZHIP IHC constitutes a fast, low-cost and conservative tissue-consuming method to detect CXorf67 overexpression, suitable for small samples (particularly in brainstem biopsies), but also in samples that contain few tumor cells. The IHC may also help to evaluate the quality of resection (surgical limits). Indeed, a nuclear immunopositivity is easier to interpret than the loss of H3K27me3. Our work highlighted the robust specificity of EZHIP staining in all PF ependymomas, group PFA and in all DMG, H3-wildtype with EZHIP overexpression, ruling out the main differential diagnoses encountered in children in the brainstem and in the posterior fossa (Table 1). All germinomas except two exhibited a strong positivity for EZHIP concomitant with a loss of H3K27me3 as published previously [2, 7]. Concerning HGG, MYCN-amplified none of our 9 cases (confirmed by DNA-methylation profiling and previously reported [5, 6]), were immunopositive, contrarily to a previous study which reported an expression of EZHIP in 13% of cases [1]. Moreover, this biomarker may represent a diagnostic but also a prognostic tool. Indeed, PFA-EPN were associated with a poorer prognosis than PFB-EPN, and patients with DMG overexpressing EZHIP presented a better overall survival compared to DMG, H3K27-mutant [1].
To conclude, we demonstrated that EZHIP IHC is a highly specific and sensitive biomarker for identifying PFA-EPN and DMG, H3-wildtype, with EZHIP overexpression, and should be part of the neuropathologist’s routine panel of antibodies.
The authors declare that they have no conflict of interest directly related to the topic of this article.
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.
Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.
Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.
Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.